Hikma update on colchicine

Hikma update on colchicine

London, 10 October 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that the United States District Court for the District of Delaware has granted Takeda Pharmaceuticals U.S.A., Inc.'s ("Takeda") motion for a temporary restraining order in relation to further distribution of Hikma's FDA-approved colchicine 0.6mg capsules for the prophylaxis of gout flares, while the court considers Takeda's motion for a preliminary injunction. 

Hikma received FDA approval of its New Drug Application for colchicine 0.6mg capsules on 30 September 2014.

The litigation will continue later this month and Hikma will work constructively for a positive outcome.

--  ENDS  --

Hikma Pharmaceuticals PLC                                                      
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations              +44 (0)20 7399 2760
Lucinda Henderson, Deputy Investor Relations Director                                               +44 (0)20 7399 2765

FTI Consulting                                                                                 
Ben Atwell/ Matthew Cole/ Julia Phillips                                                                             +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

This information is provided by RNS
The company news service from the London Stock Exchange


Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.